Ibuprofen
ApprovedCompleted 0 watching 0 views this week🔥 Hot
84
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Heat
Conditions
Heat, Pain
Trial Timeline
Nov 1, 2014 → Mar 1, 2015
NCT ID
NCT02327338About Ibuprofen
Ibuprofen is a approved stage product being developed by Pfizer for Heat. The current trial status is completed. This product is registered under clinical trial identifier NCT02327338. Target conditions include Heat, Pain.
Hype Score Breakdown
Clinical
30
Activity
20
Company
9
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02327338 | Approved | Completed |
Competing Products
13 competing products in Heat
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Thermal stress and performance without a pre-cooling protocol | Petros Pharmaceuticals | Pre-clinical | 15 |
| AZD7053 + Placebo | AstraZeneca | Phase 1 | 33 |
| Ticagrelor 90 mg whole tablet + Ticagrelor 90 mg tablet crushed + Dispersed ticagrelor 90 mg tablet suspended in water - nasogastric tube | AstraZeneca | Phase 1 | 33 |
| Treatment A (BDA MDI HFO) + Treatment B (BDA MDI HFA) | AstraZeneca | Phase 1 | 33 |
| Selumetinib + Sirolimus | AstraZeneca | Phase 2 | 52 |
| Pembrolizumab | Merck | Phase 2 | 52 |
| imatinib mesylate | Novartis | Phase 2/3 | 65 |
| everolimus + bevacizumab | Novartis | Phase 2 | 52 |
| PF-06700841 + Itraconazole | Pfizer | Phase 1 | 32 |
| Nivolumab + Ipilimumab | Bristol Myers Squibb | Phase 1 | 32 |
| Immune Globulin (Human) | Grifols | Approved | 82 |
| Ryanodex and Standard of Care | Eagle Pharmaceuticals | Phase 3 | 69 |
| Dantrolene sodium for injectable suspension | Eagle Pharmaceuticals | Phase 2 | 44 |